Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions for animal identification, monitoring and traceability; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Merck & Company Inc.

Canaccord Genuity analyst reiterated a Buy rating on Marks Electrical Group Plc yesterday and set a price target of p55.00. The word on The Street ...

Canaccord Genuity Reaffirms Their Buy Rating on Marks Electrical Group Plc (MRK)

In a report released today, from Shore Capital reiterated a Hold rating on Marks Electrical Group Plc, with a price target of p50.00. The word on T...

Shore Capital Reaffirms Their Hold Rating on Marks Electrical Group Plc (MRK)

Stocks ended the week higher as investors looked past policy noise and leaned back into risk assets. The Dow Jones Industrial Average (DJIA) rose 0...

The Week That Was, The Week Ahead: Macro and Markets, June 14

The Schwab U.S. Dividend Equity ETF ($SCHD) has climbed by roughly 19% since the start of the year, riding on the back of solid financial and stock...

SCHD Is Up Almost 20% YTD — How Higher Can It Go?

Exchange-traded funds can be an attractive choice for investors seeking broad market exposure and reduced stock-specific risk. Interestingly, ETFs ...

Best ETFs to Invest In, According to AI Analyst, 6/12/2026

Investors often prefer exchange-traded funds (ETFs) for their diversification benefits and low cost. They can choose from a vast universe of ETFs b...

Best ETFs to Invest In, According to AI Analyst, 6/5/2026

TipRanks’ AI analyst currently sees roughly 14% upside for the Schwab U.S. Dividend Equity ETF ($SCHD) compared to 9% by human analysts. The AI ana...

SCHD: Why AI Sees More Upside Than Human Analysts Do

Goldman Sachs analyst Asad Haider maintained a Buy rating on Merck & Company on June 2 and set a price target of $137.00. The company’s shares clos...

Goldman Sachs Reaffirms Their Buy Rating on Merck & Company (MRK)

UBS analyst Michael Yee maintained a Buy rating on Merck & Company today and set a price target of $145.00. According to TipRanks, Yee is a 2-star ...

Merck & Company (MRK) Receives a Buy from UBS

In a report released today, Louise Chen from Scotiabank maintained a Buy rating on Merck & Company, with a price target of $136.00. According to Ti...

Scotiabank Sticks to Their Buy Rating for Merck & Company (MRK)

This article highlights three ETFs rated by TipRanks’ AI analyst as Outperform and carrying at least 10% upside potential from Wall Street analysts...

AI Analyst Picks 3 Best ETFs with 10%+ Upside, 6/1/2026

Investors are increasingly turning to exchange-traded funds (ETFs) for their flexibility, broad market access, diversification, and liquidity. Give...

Best ETFs to Invest In, According to AI Analyst, 5/29/2026

Merck & Company ( ($MRK) ) has issued an announcement. At Merck & Co., Inc.’s Annual Meeting of Shareholders held on May 26, 2026, all nominated di...

Merck Shareholders Back Board, Pay and Auditor Ratification

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Merck & Company (MRK) and Qiagen (QGEN) with bullish...

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Qiagen (QGEN)

In a report released yesterday, Peter Spengler from DZ BANK AG maintained a Buy rating on Merck KGaA. The company’s shares closed last Monday at €1...

DZ BANK AG Sticks to Their Buy Rating for Merck KGaA (0O14)

Merck & Company ( ($MRK) ) has shared an announcement. On May 22, 2026, Merck & Co., Inc. completed an underwritten public offering of multiple tra...

Merck Completes $6 Billion Multi-Tranche Senior Notes Offering

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Merck & Company (MRK) and BioInvent International AB...

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and BioInvent International AB (OtherBOVNF)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Regeneron (REGN) and Merck & Company (MRK) with bull...

Analysts Are Bullish on These Healthcare Stocks: Regeneron (REGN), Merck & Company (MRK)

Exchange-traded funds (ETFs) remain a popular investment choice as investors seek diversification, lower costs, and exposure to fast-growing sector...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MRK	$113.87	-1.36%	29.52M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MRK	$113.87	-1.4%	29.52M
3
4
5
6

MRK

MRK

Get Merck & Company Inc. Data in Excel

Get Merck & Company Inc. Data in Excel